Buy Cheap Generic Hepsera, Adefovir Dipivoxil Tablet

Hepsera bearing the generic name Adefovir Dipivoxil was given approval by the US Food and Drug Administration (FDA) in September 2002 for the treatment of continuing and recurrent hepatitis B in adults with indication of active viral reproduction and either indication of relentless rises in serum aminotransferases or histologically dynamic illness. Hepsera, offered as an oral 10 mg pill, is the foremost nucleotide (the fundamental structural unit of nucleic acids, DNA or RNA) analog to be acceptable for this indication.

Mechanism of Action

Adefovir Dipivoxil is basically a diester prodrug (inactive or less active form) of Adefovir, which is an open-chain nucleotide analogue of adenosine monophosphate (a nucleotide detected in muscle cells and crucial in metabolic process). Adefovir is metabolized in vivo to the active metabolite, Adefovir diphosphate, by cellular kinases (enzymes that catalyze the transition of a proenzyme to an active enzyme).

Adefovir diphosphate suppresses HBV DNA polymerase, the enzyme responsible for DNA reproduction (reverse transcriptase) by contending with the natural substance deoxyadenosine triphosphate and by inducing DNA chain expiration after its inclusion into viral DNA (according to the prescription label approved by FDA).

Outcomes of Clinical Trials

The data obtained from clinical trials pointed out that treatment with Hepsera (Adefovir Dipivoxil) was connected with inhibition of hepatitis B virus (HBV) DNA to untraceable levels in 80 percent of participants who underwent 12 to 15 months of medical intervention. These outcomes make complete earlier data portraying Adefovir Dipivoxil as a chemical compound that continues to be active against all clinically applicable strains of hepatitis B virus trialed up to now. The open-label trial comprised 23 participants with degenerative HBV infection who were unsuccessful with the antiviral drug Lamivudine (3TC).

In June 2001, interim data of phase III clinical trial assessing Adefovir Dipivoxil expressed that the trial conformed to its principal terminus of betterment in liver histology at week 48 in comparison to standard. The two-year, randomly distributed, double-blind, placebo-regulated test registered 515 participants with persistent HBV contagion. Two dosages of Hepsera were weighed up, namely the 10 mg dose that was FDA-approved and an investigative 30 mg dose. Enhancement in liver microscopic anatomy was detected in 53 percent of participants administered Adefovir Dipivoxil 10 mg, compared to 25 percent of placebo-handled participants, as evaluated by liver diagnostic tests or biopsies. Identical effectiveness outcomes were received for Adefovir Dipivoxil 10 and 30 mg doses on the basis of liver histology, seroconversion and decrease in HBV DNA.

In September 2001, first round phase III trial outcomes showed that treatment with Hepsera (Adefovir Dipivoxil) 10 mg pill taken one time daily for 48 weeks was linked with progress in liver histology in 64 percent of medication-treated participants when compared with 33 percent of participants who took placebo.

Side Effects

The most familiar adverse effects of Hepsera described all through clinical trials included:

Asthenia (an unusual loss of strength)
Headache
Pain in the abdomen
Sickness
Gas
Looseness of the bowels
Indigestion

Furthermore, untoward side effects complained of in pre- and post-liver transplantation patients comprised, but were not confined:

Feverishness
Throwing up
Hepatic failure
Elevations in serum creatinine
Kidney dysfunction
Inadequate excretion of wastes by the kidneys
Rises in levels of ALT and AST
Unnatural liver function

Synonym

United States: Hepsera
United Kingdom: Hepsera
Switzerland: Hepsera
Sweden: Hepsera
Spain: Hepsera
Singapore: Hepsera
Norway: Hepsera
Italy: Hepsera
Israel: Hepsera
Ireland: Hepsera
India: Adsera
Hong Kong: Hepsera
Greece: Hepsera
Germany: Hepsera
Denmark: Hepsera
Belgium: Hepsera
Australia: Hepsera
Argentina: Hepsera